# | Title | Journal | Year | Citations |
---|
1 | CD19: a biomarker for B cell development, lymphoma diagnosis and therapy | Experimental Hematology and Oncology | 2012 | 398 |
2 | CD133: a stem cell biomarker and beyond | Experimental Hematology and Oncology | 2013 | 243 |
3 | Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis | Experimental Hematology and Oncology | 2012 | 227 |
4 | Complex roles of cAMP–PKA–CREB signaling in cancer | Experimental Hematology and Oncology | 2020 | 202 |
5 | CD44 as a tumor biomarker and therapeutic target | Experimental Hematology and Oncology | 2020 | 177 |
6 | Leukemia incidence trends at the global, regional, and national level between 1990 and 2017 | Experimental Hematology and Oncology | 2020 | 129 |
7 | Mechanisms for estrogen receptor expression in human cancer | Experimental Hematology and Oncology | 2018 | 127 |
8 | Breast cancer brain metastases: the last frontier | Experimental Hematology and Oncology | 2015 | 124 |
9 | Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine | Experimental Hematology and Oncology | 2018 | 119 |
10 | Risk factors and outcome of COVID-19 in patients with hematological malignancies | Experimental Hematology and Oncology | 2020 | 119 |
11 | The role of neoantigen in immune checkpoint blockade therapy | Experimental Hematology and Oncology | 2018 | 99 |
12 | Childhood B-acute lymphoblastic leukemia: a genetic update | Experimental Hematology and Oncology | 2014 | 97 |
13 | Digitoxin and its analogs as novel cancer therapeutics | Experimental Hematology and Oncology | 2012 | 96 |
14 | Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature | Experimental Hematology and Oncology | 2015 | 86 |
15 | Emerging therapies in advanced hepatocellular carcinoma | Experimental Hematology and Oncology | 2018 | 85 |
16 | The development of bispecific antibodies and their applications in tumor immune escape | Experimental Hematology and Oncology | 2017 | 83 |
17 | Advances and perspectives of PARP inhibitors | Experimental Hematology and Oncology | 2019 | 81 |
18 | Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies | Experimental Hematology and Oncology | 2013 | 79 |
19 | SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients | Experimental Hematology and Oncology | 2020 | 74 |
20 | Polo-like kinase 1 as target for cancer therapy | Experimental Hematology and Oncology | 2012 | 73 |
21 | Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety | Experimental Hematology and Oncology | 2012 | 71 |
22 | Ibrutinib for B cell malignancies | Experimental Hematology and Oncology | 2014 | 68 |
23 | Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia | Experimental Hematology and Oncology | 2017 | 64 |
24 | Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment | Experimental Hematology and Oncology | 2017 | 64 |
25 | Engineering better chimeric antigen receptor T cells | Experimental Hematology and Oncology | 2020 | 64 |
26 | Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC | Experimental Hematology and Oncology | 2021 | 64 |
27 | Research progress on dendritic cell vaccines in cancer immunotherapy | Experimental Hematology and Oncology | 2022 | 61 |
28 | Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL | Experimental Hematology and Oncology | 2017 | 60 |
29 | A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017 | Experimental Hematology and Oncology | 2021 | 59 |
30 | The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis | Experimental Hematology and Oncology | 2019 | 58 |
31 | GATA family transcriptional factors: emerging suspects in hematologic disorders | Experimental Hematology and Oncology | 2015 | 57 |
32 | Cohesin mutations in myeloid malignancies: underlying mechanisms | Experimental Hematology and Oncology | 2014 | 54 |
33 | Macrophage, the potential key mediator in CAR-T related CRS | Experimental Hematology and Oncology | 2020 | 54 |
34 | Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia | Experimental Hematology and Oncology | 2020 | 54 |
35 | YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition | Experimental Hematology and Oncology | 2021 | 54 |
36 | Targeted and novel therapy in advanced gastric cancer | Experimental Hematology and Oncology | 2019 | 53 |
37 | Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies | Experimental Hematology and Oncology | 2021 | 53 |
38 | Current management and prognostic features for gastrointestinal stromal tumor (GIST) | Experimental Hematology and Oncology | 2012 | 52 |
39 | Long noncoding RNAs: pivotal regulators in acute myeloid leukemia | Experimental Hematology and Oncology | 2015 | 52 |
40 | Selective inhibitors of nuclear export (SINE) in hematological malignancies | Experimental Hematology and Oncology | 2015 | 52 |
41 | Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia | Experimental Hematology and Oncology | 2014 | 51 |
42 | Successful treatment of a Caucasian case of multifocal Castleman’s disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report | Experimental Hematology and Oncology | 2015 | 51 |
43 | Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia | Experimental Hematology and Oncology | 2013 | 49 |
44 | Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity | Experimental Hematology and Oncology | 2015 | 49 |
45 | Role of m6A writers, erasers and readers in cancer | Experimental Hematology and Oncology | 2022 | 49 |
46 | Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma | Experimental Hematology and Oncology | 2020 | 48 |
47 | Clinical implications of recurrent gene mutations in acute myeloid leukemia | Experimental Hematology and Oncology | 2020 | 47 |
48 | MiRNA-mediated EMT and CSCs in cancer chemoresistance | Experimental Hematology and Oncology | 2021 | 47 |
49 | Thalidomide and its analogues in the treatment of Multiple Myeloma | Experimental Hematology and Oncology | 2012 | 45 |
50 | Effectiveness of AMD3100 in treatment of leukemia and solid tumors: from original discovery to use in current clinical practice | Experimental Hematology and Oncology | 2015 | 44 |